###begin article-title 0
###xml 141 146 <span type="species:ncbi:9606">Human</span>
20-Hydroxycholecalciferol, Product of Vitamin D3 Hydroxylation by P450scc, Decreases NF-kappaB Activity by Increasing IkappaBalpha Levels in Human Keratinocytes
###end article-title 0
###begin p 1
Conceived and designed the experiments: ZJ LMP ATS. Performed the experiments: ZJ MAZ RCT DAD MNN. Analyzed the data: ZJ MAZ RCT LMP ATS. Contributed reagents/materials/analysis tools: ZJ RCT. Wrote the paper: ZJ RCT LMP ATS.
###end p 1
###begin p 2
The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes. Since nuclear factor-kappaB (NF-kappaB) plays a pivotal role in the regulation of cell proliferation, differentiation and apoptosis, we examined the capability of 20-hydroxycholecalciferol to modulate the activity of NF-kappaB, using 1,25-dihydroxycholecalciferol (calcitriol) as a positive control. 20-hydroxycholecalciferol inhibits the activation of NFkappaB DNA binding activity as well as NF-kappaB-driven reporter gene activity in keratinocytes. Also, 20-hydroxycholecalciferol induced significant increases in the mRNA and protein levels of the NF-kappaB inhibitor protein, IkappaBalpha, in a time dependent manner, while no changes in total NF-kappaB-p65 mRNA or protein levels were observed. Another measure of NF-kappaB activity, p65 translocation from the cytoplasm into the nucleus was also inhibited in extracts of 20-hydroxycholecalciferol treated keratinocytes. Increased IkappaBalpha was concomitantly observed in cytosolic extracts of 20-hydroxycholecalciferol treated keratinocytes, as determined by immunoblotting and immunofluorescent staining. In keratinocytes lacking vitamin D receptor (VDR), 20-hydroxycholecalciferol did not affect IkappaBalpha mRNA levels, indicating that it requires VDR for its action on NF-kappaB activity. Comparison of the effects of calcitrol, hormonally active form of vitamin D3, with 20-hydrocholecalciferol show that both agents have a similar potency in inhibiting NF-kappaB. Since NF-kappaB is a major transcription factor for the induction of inflammatory mediators, our findings indicate that 20-hydroxycholecalciferol may be an effective therapeutic agent for inflammatory and hyperproliferative skin diseases.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 75 78 75 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Lehmann1">[1]</xref>
###xml 80 83 80 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick1">[2]</xref>
###xml 85 88 85 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle1">[3]</xref>
###xml 200 203 200 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick1">[2]</xref>
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Webb1">[4]</xref>
###xml 210 213 210 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick2">[5]</xref>
###xml 358 359 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 441 444 441 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle1">[3]</xref>
###xml 582 585 582 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski1">[6]</xref>
###xml 587 590 587 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 592 595 592 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski3">[8]</xref>
###xml 597 600 597 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey1">[9]</xref>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey3">[11]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski4">[12]</xref>
###xml 718 722 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey4">[13]</xref>
###xml 1009 1017 1009 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g001">Figure 1</xref>
###xml 1019 1022 1019 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 1024 1028 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
###xml 1030 1034 1030 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey3">[11]</xref>
###xml 1213 1216 1213 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Lehmann2">[14]</xref>
###xml 1287 1290 1287 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski3">[8]</xref>
###xml 1504 1508 1504 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human keratinocytes have the ability to metabolize vitamin D3 autonomously [1], [2], [3]. Not only are they the site of conversion of 7-dehydrocholesterol (7DHC) to vitamin D3 following UVB-radiation [2], [4], [5], but they also express enzymes to hydroxylate vitamin D3 to the hormonally active form known as calcitriol or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Thus, keratinocytes are the site of production and the target for vitamin D3 [3]. We have recently identified new pathway for metabolism of vitamin D and pro-vitamin D that is catalyzed by cytochrome P450scc (CYP11A1) [6], [7], [8], [9], [10], [11], [12], the enzyme catalyzing the conversion of cholesterol to pregnenolone for steroid hormone synthesis [13]. 20-Hydroxyvitamin D3 (20(OH)D3) is the major product of P450scc activation of vitamin D3 as well as an intermediate in the sequential synthesis of other hydroxylated derivatives including 20,23-dihydroxyvitamin D3 (20,23(OH)2D3 and 17,20,23-trihydroxyvitamin D3 (17,20,23(OH)3D3) (see Figure 1) [7], [10], [11]. We postulated that 20(OH)D3 could have systemic effects when produced in organs expressing high levels of P450scc, such as adrenal cortex, corpus luteum, follicles and placenta [7], [14], while in organs expressing low levels of P450scc, such as skin [8], 20(OH)D3 could serve local paracrine, autocrine or intracrine roles. In fact, we have recently demonstrated that 20(OH)D3 can stimulate differentiation and inhibit proliferation of keratinocyte cultured in vitro [15].
###end p 4
###begin title 5
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
P450scc (CYP11A1) can hydroxylate vitamin D3 to 20-hydroxycholecalciferol with following sequential metabolism to other hydroxyderivatives [10].
###end title 5
###begin p 6
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Deeb1">[16]</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle2">[17]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bouillon1">[18]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-vandenBemd1">[19]</xref>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Spina1">[20]</xref>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick3">[21]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Dusso1">[22]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Nagpal1">[23]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 289 290 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Saito1">[24]</xref>
###xml 379 382 379 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick1">[2]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick3">[21]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick4">[25]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle3">[26]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Wiseman1">[27]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick4">[25]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle3">[26]</xref>
###xml 527 531 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick5">[28]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle4">[29]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle5">[30]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick6">[31]</xref>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle6">[32]</xref>
Vitamin D3 has a wide variety of actions in autoimmune diseases and cancer [16], [17], [18], [19], [20] as well as on bone physiology and blood pressure [21], [22], [23]. The biological role of its metabolite 20(OH)D3 is only partially known [15], while it is well documented that 1,25(OH)2D3 and its derivatives [24] have diverse biological activities on multiple cell lineages [2], [21], [25], [26], [27], including modulation of the skin immune system (SIS) and protection of the skin against UVB-induced damage [25], [26], [28], [29], [30], [31], [32].
###end p 6
###begin p 7
###xml 192 196 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Li1">[33]</xref>
###xml 280 284 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-VanWaes1">[34]</xref>
###xml 286 290 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Liu1">[35]</xref>
###xml 292 296 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Umezawa1">[36]</xref>
###xml 502 506 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Grone1">[37]</xref>
###xml 508 512 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Freedberg1">[38]</xref>
###xml 584 588 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Banno1">[39]</xref>
###xml 590 594 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Banno2">[40]</xref>
###xml 748 752 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Hayden1">[41]</xref>
###xml 990 994 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Li1">[33]</xref>
###xml 1100 1104 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Du1">[42]</xref>
###xml 1106 1110 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Wei1">[43]</xref>
###xml 1112 1116 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Yang1">[44]</xref>
###xml 1118 1122 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pfeffer1">[45]</xref>
Inflammation and proliferation are regulated by a plethora of transcription factors, with nuclear factor-kappaB (NF-kappaB) considered to be a master regulator of these processes (reviewed in [33]). NF-kappaB is also important in the development, prevention and therapy of cancer [34], [35], [36]. NF-kappaB activity is stimulated by many pathways that converge on IkappaB kinases, including the signaling pathways activated by various cytokines, such as the proinflammatory cytokine IL-1 (reviewed in [37], [38]), lipopolysaccharide (LPS) and tumor necrosis factor alpha (TNF-alpha) [39], [40]. In mammals, the NF-kappaB family of proteins includes NF-kappaB1 (p105 processed to p50), NF-kappaB2 (p100 processed to p52), RelA (p65), RelB and cRel [41]. Phosphorylation and subsequent degradation of IkappaB proteins allow for translocation of cytoplasmic NF-kappaB into the nucleus, where NF-kappaB binds to specific promoter/enhancer elements to regulate the expression of specific genes [33]. NF-kappaB regulated genes play important roles in inflammation, immunity, cell growth and cell survival [42], [43], [44], [45].
###end p 7
###begin p 8
###xml 529 533 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Du1">[42]</xref>
###xml 535 539 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pomerantz1">[46]</xref>
###xml 463 481 <span type="species:ncbi:10376">Epstein-Barr virus</span>
NF-kappaB activation is mediated through the activation of specific IkappaB kinases (IKKs) and the subsequent phosphorylation of IkappaB. The pathway leading to proteolysis of IkappaB is denoted as the canonical NF-kappaB activation pathway. NF-kappaB activation also occurs through the 'noncanonical' pathway, which does not involve IkappaB degradation and is activated by various agents, including interferon-alpha/beta, lipopolysaccharide, the LMP1 protein of Epstein-Barr virus, B-cell activating factor and lymphotoxin-beta [42], [46].
###end p 8
###begin p 9
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Schon1">[47]</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Nagpal2">[48]</xref>
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Masuda1">[49]</xref>
###xml 210 211 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle7">[50]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Oda1">[51]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Hawker1">[52]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zella1">[53]</xref>
###xml 506 510 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Lippens1">[54]</xref>
###xml 551 552 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 668 672 652 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Riis1">[55]</xref>
###xml 726 730 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-CohenLahav1">[56]</xref>
###xml 732 736 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-CohenLahav2">[57]</xref>
###xml 757 758 741 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 863 867 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Sun1">[58]</xref>
###xml 522 527 <span type="species:ncbi:9606">human</span>
###xml 707 713 <span type="species:ncbi:10090">murine</span>
Vitamin D and various synthetic vitamin D analogues have been widely used in the treatment of psoriasis [47] and other inflammatory/hyperproliferative skin disorders [48], [49]. The cellular actions of 1,25(OH)2D3, the bioactive form of vitamin D, are not fully understood, but its effects have traditionally been ascribed to its binding to the vitamin D receptor (VDR) [50], [51], [52], [53]. NF-kappaB plays an important role in protecting keratinocytes against apoptosis during programmed cornification [54]. In normal human keratinocytes, 1,25(OH)2D3 reduces NF-kappaB DNA binding activity by increasing IkappaBalpha protein levels, which inhibits IL-8 production [55]. A similar effect is also seen in murine macrophages [56], [57]. Effects of 1,25(OH)2D3 on NF-kappaB that are not mediated by the VDR have also been reported for fibroblasts lacking the VDR [58].
###end p 9
###begin p 10
###xml 134 135 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 258 262 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Ren1">[59]</xref>
###xml 439 440 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 594 598 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle3">[26]</xref>
###xml 600 604 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bar1">[60]</xref>
###xml 704 707 696 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 778 782 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski5">[61]</xref>
###xml 864 868 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zmijewski1">[62]</xref>
###xml 1002 1005 990 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 1007 1010 995 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski3">[8]</xref>
###xml 1012 1015 1000 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey1">[9]</xref>
###xml 1017 1021 1005 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
###xml 1023 1027 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey3">[11]</xref>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 384 389 <span type="species:ncbi:9606">human</span>
In the present study we have examined the effects of 20(OH)D3 on NF-kappaB signaling in comparison to well defined effects of 1,25(OH)2D3. Since NF-kappaB dysregulation induces malignant transformation of HaCaT keratinocytes, but not of normal keratinocytes [59], we used in these studies both immortalized human HaCaT keratinocytes and primary epidermal keratinocytes, isolated from human neonatal foreskin (HEKn). The effects of 1,25(OH)2D3 on both expression of genes involved in its metabolism and the biological activity of the encoded proteins have previously been studied in these cells [26], [60]. Recent data from our laboratories indicates that 20(OH)D3 can be produced by adrenal mitochondria [7], that adrenal glands ex-vivo can transform 7DHC to 5,7-diene products [61] that in the skin can be converted to biologically active vitamin D-like products [62]. Therefore, action of 20(OH)D3 on NF-kappaB activity would suggest a role for a novel endogenous secosteroidogenic metabolic pathway [7], [8], [9], [10], [11] in the regulation of the systemic and cutaneous immune activity.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
20-Hydroxycholecalciferol inhibits NF-kappaB DNA binding activity in keratinocytes
###end title 12
###begin p 13
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 613 629 601 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g002">figure 2A and 2C</xref>
###xml 1013 1014 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1290 1294 1258 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek2">[63]</xref>
###xml 366 371 <span type="species:ncbi:9606">human</span>
In initial experiments we determined that 20(OH)D3 at 100 nM was optimal for inducing biological actions like stimulation of keratinocytes differentiation and inhibition of cell proliferation [15]. Next we examined the effect of 20(OH)D3 on NF-kappaB activity in keratinocytes by assaying nuclear extracts of 20(OH)D3-stimulated cells by DNA-binding assays. Primary human keratinocytes and HaCaT cells were incubated with 100 nM 20(OH)D3, nuclear extracts were prepared and incubated with an NF-kappaB oligonucleotide probe based on the kappaB binding site in the immunoglobulin light chain enhancer. As shown in figure 2A and 2C, a time dependent decrease in nuclear protein binding to the kappaB response element was observed in extracts from 20(OH)D3-treated cells. Inhibition of NF-kappaB activity was observed within 30 minutes of 20(OH)D3 addition. Maximum inhibition was reached by 4 hours, and inhibition persisted up to 24 hours. This effect was no longer observed after 48 hours. Treatment with 1,25(OH)2D3 also had similar inhibitory effect of NF-kappaB activity (data not shown). High basal NF-kappaB activity in HaCaT cells is probably due to serum deprivation of cells, since previously we have demonstrated that serum deprivation triggers NF-kappaB activation in HaCaT cells [63].
###end p 13
###begin title 14
20(OH)D3 treatment inhibits the activation of NFkappaB DNA binding activity in keratinocytes.
###end title 14
###begin p 15
###xml 36 41 <span type="species:ncbi:9606">human</span>
Nuclear extracts were prepared from human keratinocytes, normal and HaCaT, treated with 100 nM 20(OH)D3 for indicated time periods, and were subjected to EMSA (A,C). Nuclear extracts were preincubated with NF-kappaB antibodies (p65 and p50) and subjected to supershift assay (B,D). "Cold" represents nuclear extract preincubated with an excess of unlabelled oligonucleotide.
###end p 15
###begin p 16
###xml 220 236 212 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g002">figure 2B and 2D</xref>
In order to determine the composition of 20(OH)D3-induced NF-kappaB complexes, nuclear extracts were preincubated with antibodies against the p65 and p50 NF-kappaB proteins and analyzed by supershift assays. As shown in figure 2B and 2D, the 20(OH)D3-induced complex contains both p50 and p65 proteins. The specificity of the binding to the kappaB probe was determined by incubating nuclear extract with excess unlabeled (cold) NF-kappaB oligonucleotide. Since excess unlabeled NF-kappaB oligonucleotide competed out DNA binding to the kappaB probe, NF-kappaB binding was considered specific.
###end p 16
###begin title 17
20-Hydroxycholecalciferol inhibits NFkappaB-driven reporter gene activity in keratinocytes
###end title 17
###begin p 18
###xml 228 234 220 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>
###xml 438 439 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 492 498 476 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>
###xml 648 655 632 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>
###xml 791 798 775 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>
###xml 822 823 806 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1022 1029 998 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>
###xml 254 259 <span type="species:ncbi:9606">human</span>
###xml 553 558 <span type="species:ncbi:9606">human</span>
In order to determine functional consequences of the decreased NF-kappaB DNA binding activity in the keratinocytes treated with 20(OH)D3, we performed gene reporter assays to determine NF-kappaB driven transcriptional activity (Fig. 3). HaCaT and normal human keratinocytes were transiently transfected with the pNFkappaB-Luc construct, which contained the firefly luciferase reporter gene driven by NF-kappaB. In the presence of 1,25(OH)2D3 or 20(OH)D3, basal luciferase activity decreased (Fig. 3). The inhibitory effect was more pronounced in normal human keratinocytes, with approximately a 2.5-fold decrease in the reporter activity (p<0.01) (Fig. 3A). In immortalized keratinocytes (HaCaT) the decrease in activity was less pronounced, but was also statistically significant (p<0.05) (Fig. 3A). 20(OH)D3 and 1,25(OH)2D3 had similar potency in inhibiting the NF-kappaB driven reporter in keratinocytes. Interestingly, NF-kappaB activity was significantly inhibited even after 24 hours of treatment with either agent (Fig. 3A).
###end p 18
###begin title 19
20(OH)D3 treatment inhibits the activation of NFkappaB-dependant activity in keratinocytes.
###end title 19
###begin p 20
###xml 125 126 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 343 348 <span type="species:ncbi:9606">human</span>
Keratinocytes were transiently transfected with a NFkappaB-Luc construct for 24 h then treated with 100 nM 20(OH)D3, 1,25(OH)2D3 or ethanol as a vehicle for the indicated time periods (A), or additionally stimulated with LPS (1 microg/ml) or IL-1alpha (10 ng/ml) for 30 min (B and C, respectively). Cell lysates prepared from HaCaT and normal human keratinocytes were assayed for luciferase activity. The data from six experiments performed in quadruplicate are presented as means+/-STDEV. *p<0.05 and **p<0.01 between control (non treated cells) and treated cells.
###end p 20
###begin p 21
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 231 240 219 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Figure 3B</xref>
###xml 471 472 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 582 583 558 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 758 759 726 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 955 956 919 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1050 1051 1010 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1271 1272 1219 1220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1427 1428 1367 1368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 884 889 <span type="species:ncbi:9606">human</span>
To further characterize the inhibitory activity of 20(OH)D3 and 1,25(OH)2D3, NF-kappaB activity in HaCaT and normal human keratinocytes was stimulated by two agents known to induce NF-kappaB activity, LPS or IL-1alpha. As shown in Figure 3B, both LPS and IL-1alpha increased NF-kappaB-driven luciferase activity in HaCaT cells and normal human keratinocytes, as compared to cells treated with vehicle (<0.01% ethanol). We next examined the effects of 20(OH)D3 or 1,25(OH)2D3 on luciferase activity in HaCaT cells stimulated with LPS or IL-1alpha. Treatment with 20(OH)D3 or 1,25(OH)2D3 resulted in a statistically significant (p<0.05) decrease in NF-kappaB-driven luciferase expression in HaCaT cells stimulated by LPS or IL-1alpha with 20(OH)D3 and 1,25(OH)2D3 exhibiting similar potencies in inhibiting NF-kappaB activity. We than analyzed luciferase activity in cell extracts from human epidermal keratinocytes (HEKn), treated with 20(OH)D3 or 1,25(OH)2D3 and stimulated with LPS or IL-1alpha. Interestingly, the inhibition by 20(OH)D3 or 1,25(OH)2D3 of NF-kappaB activity was greater when the keratinocytes were stimulated with LPS as compared to IL-1alpha. 20(OH)D3 was slightly less potent in inhibiting NF-kappaB activity in keratinocytes when compared to 1,25(OH)2D3. Thus, despite the cell-type differences in the stimulation of NF-kappaB-dependent transcription activity by LPS versus IL-1alpha, 20(OH)D3 and 1,25(OH)2D3 inhibited NF-kappaB-dependent transcription.
###end p 21
###begin title 22
20-Hydroxycholecalciferol inhibits translocation of the p65 NFkappaB protein induced by IL-1alpha in keratinocytes
###end title 22
###begin p 23
###xml 777 783 741 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g004">Fig. 4</xref>
To further characterize the inhibitory effect of 20(OH)D3 on NF-kappaB activity, we examined the cellular localization of the p65 NF-kappaB protein and the IkappaBalpha inhibitory protein in keratinocytes by fluorescent microscopy. As is usually observed in unstimulated cells, NF-kappaB is localized mainly in the cytoplasm with only minor nuclear staining detected. Stimulation of cells by IL-1alpha induced p65 translocation from the cytoplasm into the nucleus, indicative of the NF-kappaB activation. In contrast, treatment of cells with 20(OH)D3 nearly completely blocked the nuclear translocation of p65. In addition, there was a detectable increase in IkappaBalpha protein localized in the cytoplasm after treatment with 20(OH)D3 in comparison to vehicle-treated cells (Fig. 4). Similar results were obtained when HaCaT and normal keratinocytes were treated with 20(OH)D3 for 1, 4 or 24 hours (data not shown).
###end p 23
###begin title 24
20(OH)D3 inhibits the translocation of NFkappaB-p65 complex into the nucleus and increases the expression of IkappaBalpha in the cytosol of keratinocytes.
###end title 24
###begin p 25
###xml 8 13 <span type="species:ncbi:9606">human</span>
Primary human keratinocytes, third passage, were incubated for 4 h in KBM medium containing KGF with 100 nM 20(OH)D3 or ethanol vehicle, stimulated with IL-1alpha for 30 min and then fixed. Cells were stained with anti IkappaBalpha or NFkappaB-p65 antibody, followed by secondary antibody linked to FITC. Nuclei were stained red with propidium iodide. Cells were analyzed using fluorescent microscope at 40x magnification.
###end p 25
###begin title 26
20-hydroxycholecalciferol increases IkappaBalpha protein levels in keratinocytes
###end title 26
###begin p 27
###xml 383 391 367 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g004">figure 4</xref>
###xml 783 790 739 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g005">Fig. 5A</xref>
###xml 817 824 773 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g005">Fig. 5C</xref>
###xml 1045 1046 985 986 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1150 1166 1090 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g005">figure 5B and 5D</xref>
###xml 1272 1273 1204 1205 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Since we demonstrated by various assays (EMSA, gene reporter assays, and immunofluorescence assays) that 20(OH)D3 inhibits NF-kappaB activity, we next examined the underlying mechanism responsible for this activity. In the classical NF-kappaB pathway, NF-kappaB activity is sequestered it in the cytoplasm by forming a complex with inhibitory IkappaB proteins. Moreover, as shown in figure 4 20(OH)D3 appears to increase cellular IkappaB levels as determined by immunofluorescent staining. To determine whether 20(OH)D3 affects the classical NF-kappaB pathway, the cellular levels of IkappaBalpha and the p65 NFkappaB were determined at various times after 20(OH)D3 addition to cells. 20(OH)D3 induced a time-dependent increase in IkappaBalpha levels in whole cell extracts of HEKn (Fig. 5A) and HaCaT keratinocytes (Fig. 5C). IkappaBalpha was increased within 1 hour of 20(OH)D3 treatment, and by 16 hours IkappaBalpha was diminished to the levels observed in untreated cells. Similar results were obtained when cells were treated with 1,25(OH)2D3. In contrast, cellular levels of p65 was unaffected by 20(OH)D3 treatment of keratinocytes. As shown figure 5B and 5D, statistically significant changes were observed for IkappaBalpha levels induced by 20(OH)D3 and 1,25(OH)2D3 expressed relative to beta-actin (p<0.05).
###end p 27
###begin title 28
20(OH)D3 increases IkappaBalpha protein concentration in keratinocytes and has no effect on NFkappaB-p65.
###end title 28
###begin p 29
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Keratinocytes, HEKn and HaCaT were stimulated for the indicated times with 100 nM 20(OH)D3, and 100 nM 1,25(OH)2D3 (HEKn keratinocytes). Cells were lysed, whole cell extracts prepared, and equivalent amounts of protein were loaded onto polyacrylamide gels. Membranes were incubated with either anti-IkappaBalpha, anti-NFkappaB-p65 or anti beta-actin (internal control) (A, C). Protein concentration expressed relative to beta-actin was significantly different to the zero-time control for IkappaBalpha (p<0.05)(B, D). Results from three separate experiments are expressed as mean+/-STDEV.
###end p 29
###begin p 30
###xml 333 340 305 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g006">Fig. 6A</xref>
###xml 460 469 420 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g006">figure 6B</xref>
###xml 121 126 <span type="species:ncbi:9606">human</span>
To further characterize the ability of 20(OH)D3 to inhibit NF-kappaB activity we stimulated NF-kappaB activity in normal human keratinocytes with IL-1alpha and determined IkappaBalpha levels in cytosolic extracts. We found that the concentration of IkappaBalpha levels were increased after treatment with 20(OH)D3 for 1 and 4 hours (Fig. 6A). Treatment of cells with 20(OH)D3 without IL-1alpha stimulation had a similar effect on IkappaBalpha levels. As shown figure 6B, statistically significant changes were observed for IkappaBalpha levels induced by 20(OH)D3 expressed relative to beta-actin (p<0.05).
###end p 30
###begin title 31
20(OH)D3 increases IkappaBalpha protein concentration in cytosolic extracts in keratinocytes.
###end title 31
###begin p 32
Normal keratinocytes were treated with 100 nM 20(OH)D3 for 1 h and 4 h and then stimulated with or without IL-1alpha (10 ng/ml) for 30 min. Cells were lysed in lysis buffer and cytosolic extracts prepared. An equal amount of proteins was loaded onto the polyacrylamide gel. Membranes were incubated with antibodies: anti-IkappaBalpha and anti beta-actin (internal control) (A). Protein concentration expressed relative to the concentration of beta-actin is shown in (B). Results are expressed as mean+/-STDEV.
###end p 32
###begin title 33
20-Hydroxycholecalciferol stimulates IkappaBalpha mRNA expression, but does not affect NF- kappaB mRNA expression in keratinocytes
###end title 33
###begin p 34
###xml 231 239 211 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g007">figure 7</xref>
###xml 715 716 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 915 916 859 860 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 343 348 <span type="species:ncbi:9606">human</span>
To determine whether the increased IkappaBalpha protein levels in cells treated with 20(OH)D3 resulting from increased IkappaBalpha mRNA expression, we measured IkappaB mRNA levels by quantitative real time PCR (qPCR). As shown in figure 7 the IkappaBalpha-mRNA levels were significantly increased after 20(OH)D3 treatment of HaCaT and normal human keratinocytes. The induction by 20(OH)D3 of IkappaBalpha mRNA expression was greater in HaCaT cells than in normal keratinocytes. The effect was already detected 1 hour after treatment and returned to basal levels by 24 hours in normal keratinocytes, while the induction of IkappaBalpha mRNA persisted up to 24 hours in HaCaT cells. Moreover, the effects of 1,25(OH)2D3 on IkappaBalpha mRNA levels were qualitatively similar to those noted for 20(OH)D3. In contrast, mRNA levels of the p50 and p65 NF-kappaB subunits were unaffected by treatment with either 1,25(OH)2D3 or 20OHD3 (data not shown).
###end p 34
###begin title 35
20(OH)D3 increases mRNA levels of IkappaBalpha in keratinocytes.
###end title 35
###begin p 36
###xml 74 75 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HEKn and HaCaT keratinocytes were treated with 100 nM 20(OH)D3 or 1,25(OH)2D3 or vehicle for the indicated period of time. Cells were then lysed and total RNA extracted. mRNA levels for IkappaBalpha were measured using reagents for RTPCR according to the manufacturer's protocol (Roche Applied Science, Manheim, Germany) and normalized relative to Cyclophylin B RNA. Data are presented as mean+/-STD (n = 3) *p<0.05 versus control, or **p<0.01 versus control. Time response in the expression of mRNA was shown for NFkappaBI (IkappaBalpha) in both cells.
###end p 36
###begin title 37
20-hydroxycholecalciferol requires VDR expression for its action on the NF-kappaB pathway in keratinocytes
###end title 37
###begin p 38
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 509 518 505 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g008">figure 8A</xref>
###xml 911 918 867 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g008">Fig. 8B</xref>
###xml 1525 1532 1453 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g008">Fig. 8D</xref>
###xml 1726 1735 1654 1663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g008">Figure 8E</xref>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:9606">Human</span>
We previously demonstrated that the action of 20(OH)D3 on human keratinocytes is dependent on VDR expression [15]. Therefore, we examined whether the effect of 20(OH)D3 on the NF-kappaB pathway was also VDR-dependent. Human keratinocytes were transiently transfected with siRNA to knock-down VDR expression, treated with 20(OH)D3 or vehicle (ethanol) and RNA isolated for gene expression analysis by qPCR In parallel experiments cell extracts were analyzed for protein expression by western blot. As shown in figure 8A transfection of keratinocytes with VDR siRNA knocked-down the levels of the vitamin D receptor by approximately approximately80%. Most importantly, knock-down of the VDR in keratinocytes completely blocked IkappaBalpha mRNA induction by 20(OH)D3 treatment. In contrast, 20(OH)D3 treatment induced a approximately2 fold increase in IkappaBalpha mRNA in cells transfected with scrambled siRNA (Fig. 8B). The mRNA levels for p50 and p65 NF-kappaB proteins were unaffected by VDR knockdown (data not shown for p50). To further test the ability of VDR knockdown on NFkappaB translocation, we transfected cells with scrambled or VDR siRNA and treated them with 20(OH)D3, and than examined the cellular localization of the p65 NF-kappaB protein and the IkappaBalpha inhibitory protein in keratinocytes by fluorescent microscopy. In summary, significantly less IkappaBalpha protein was localized in the cytoplasm after 20(OH)D3 treatment of VDR knockdown cells as compared with scrambled siRNA-treansfected cells (Fig. 8D). 20(OH)D3 treatment of cells nearly completely blocked the nuclear translocation of p65. In contrast, 20(OH)D3 treatment of VDR knockdown cells did not block the nuclear translocation of p65 (Figure 8E).
###end p 38
###begin title 39
###xml 24 29 <span type="species:ncbi:9606">human</span>
Silencing of the VDR in human keratinocytes attenuates the effects of 20(OH)D3 on IkappaBalpha or NFkappaB p65 (RelA) expression and intracellular transolaction.
###end title 39
###begin p 40
###xml 725 730 <span type="species:ncbi:9606">human</span>
Keratinocytes were transfected with 2 nM scrambled or VDR siRNA and incubated with 100 nM 20(OH)D3 or vehicle (ethanol) for 4 h. Cells were lysed after treatment and total RNA extracted. VDR mRNA (A), IkappaBalpha mRNA (B) and NFkappaB p65 (RelA) (C) levels were measured using reagents for RTPCR according to manufacturer's protocol (Roche Applied Science, Manheim, Germany) and normalized relative to Cyclophylin B RNA. Data are presented as mean+/-STD (n = 3) *p<0.05 versus control, or **p<0.01 versus control. Levels of VDR and beta-actin were assessed 24 h after transfection with VDR or scrambled siRNA, by western blotting of whole-cell extracts (A). 24 h after transfection with 2 nM scrambled or VDR siRNA, primary human keratinocytes were also incubated for 4 h in KBM medium containing KGF with 100 nM 20(OH)D3 or ethanol (vehicle), then fixed. Cells were stained with anti-IkappaBalpha antibody (green), followed by secondary antibody linked to FITC. Nuclei were stained red with propidium iodide (D). Another set of cells was stained with anti-p65 (green) (E). Cells were analyzed using a fluorescent microscope at 20x magnification.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 104 110 104 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g001">Fig. 1</xref>
###xml 112 115 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 181 186 <span type="species:ncbi:9606">human</span>
We have previously shown that 20(OH)D3 is a product of vitamin D3 metabolism by cytochrome P450scc (see Fig. 1) [7], [10]. Moreover, 20(OH)D3 has significant biological activity in human keratinocytes, as it inhibits their proliferation and stimulates their differentiation [15]. In the present study we demonstrate that 20(OH)D3 is a potent inhibitor of NF-kappaB activity. Moreover, 20(OH)D3 treatment also increases IkappaBalpha protein levels through induction of IkappaBalpha mRNA expression. IkappaBalpha induction by 20(OH)D3 requires VDR expression, indicating that 20(OH)D3 acts through the classical vitamin D and NFkappaB regulatory pathways.
###end p 42
###begin p 43
###xml 639 645 619 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>
###xml 750 756 726 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g002">Fig. 2</xref>
###xml 1116 1117 1088 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1244 1245 1212 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1260 1261 1228 1229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1325 1329 1289 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-CohenLahav2">[57]</xref>
###xml 1345 1346 1309 1310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1488 1492 1440 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Riis1">[55]</xref>
###xml 1517 1518 1469 1470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2206 2207 2122 2123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2336 2337 2252 2253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2404 2407 2320 2323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 2536 2539 2452 2455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick1">[2]</xref>
###xml 2541 2544 2457 2460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick2">[5]</xref>
###xml 828 833 <span type="species:ncbi:9606">human</span>
###xml 1421 1426 <span type="species:ncbi:9606">human</span>
The inhibitory effect of 20(OH)D3 on NF-kappaB activity in keratinocytes was shown by several complementary approaches including NF-kappaB dependent DNA binding assays, NFkappaB-driven reporter gene activity assays, as well as western blotting and immunofluorescence analysis of the translocation of p65 NF-kappaB subunit from cytoplasm into the nucleus. The inhibitory effect of 20(OH)D3 was rapid (within 30 minutes), reached a maximum by 4 hr after addition, and remained detectable as long as 24 hr after addition. The inhibitory effect of 20(OH)D3 on NF-kappaB-dependent transcriptional activity by luciferase reporter-gene analysis (Fig. 3) paralleled the time course of 20(OH)D3 inhibition of NF-kappaB-dependent DNA binding activity by EMSA (Fig. 2). The inhibitory effect of 20(OH)D3 on NF-kappaB was greater in normal human keratinocytes as compared to the effect in HaCaT keratinocytes. This discrepancy might be secondary to the immortalization of HaCaT cells, which might render them less sensitive to 20(OH)D3 treatment. Moreover, 20(OH)D3 had similar potency to that of the well characterized 1,25(OH)2D3 in inhibiting NF-kappaB activity in keratinocytes (no statistically significant difference). The vitamin D analogs, 1,25(OH)2D3 and 1,24(OH)2D3, have been previously reported to inhibit NF-kappaB activity [57]. Also, 1,25(OH)2D3 has been previously shown to regulate NF-kappaB DNA binding activity in human keratinocytes through an increase in IkappaBalpha expression [55]. In this study, 1,25(OH)2D3 inhibited NF-kappaB binding to the IL-8 kappaB binding sequence more potently than binding to the p53 kappaB binding sequence. This selectivity may be mediated through an increased IkappaBalpha expression, indicating that vitamin D analogues may exert their immunomodulatory effects through NF-kappaB regulated proinflammatory cytokines and chemokines. In our study we tested the effect of the novel analog of vitamin D3, 20(OH)D3, not only on NF-kappaB activity, but also on protein and mRNA levels, as well as the role of VDR in the effect of 20(OH)D3 on NF-kappaB. We clearly demonstrate that 20(OH)D3 inhibits NF-kappaB activity with potency similar to that of calcitriol (1,25(OH)2D3, the endogenous active form of vitamin D3). The mechanism of action or 20(OH)D3 appears to be very similar to that of 1,25(OH)2D3. The hydroxyl group of 20(OH)D3 is attached at the C20 position [7]; which is interesting since the attachment at C1 is considered to be required for full biological activity and calcemic effects [2], [5].
###end p 43
###begin p 44
###xml 150 154 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Karin1">[64]</xref>
###xml 286 290 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Grone1">[37]</xref>
###xml 427 431 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Li2">[65]</xref>
###xml 635 636 611 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1001 1005 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek2">[63]</xref>
###xml 1007 1011 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek3">[66]</xref>
###xml 1052 1053 1020 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To further characterize the action of 20(OH)D3 on inhibiting NF-kappaB activity we used known stimulators of the NF-kappaB pathway, LPS and IL-1alpha [64]. Keratinocytes can produce a plethora of cytokines including interleukin (IL)-1 and tumor necrosis factor alpha (TNF) (reviewed in [37]). IL-1 activates keratinocytes and promotes their proliferation and migration. Also, LPS is considered as a potent NF-kappaB stimulator [65]. In the present study, 20(OH)D3 was found to attenuate NF-kappaB transcriptional activity induced by both LPS or IL-1 in HaCaT cells and primary keratinocytes, and exhibited a similar potency to 1,25(OH)2D3. Interestingly, in normal keratinocytes the inhibition of NF-kappaB activity stimulated with IL-1alpha by vitamin D3 hydroxyderivatives was less pronounced then the inhibition of activity stimulated with LPS. This indicates that immortalization changes the responsiveness of keratinocytes to various stimuli, as it has been demonstrated in case of neuropeptides [63], [66]. Nonetheless, both 20(OH)D3 and 1,25(OH)2D3 inhibit NF-kappaB activity in keratinocytes induced by recognized proinflammatory stimuli.
###end p 44
###begin p 45
###xml 457 461 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pomerantz1">[46]</xref>
###xml 1667 1671 1583 1587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Du1">[42]</xref>
###xml 1098 1103 <span type="species:ncbi:9606">human</span>
Stimulation of NF-kappaB activity by LPS and IL-1alpha does not alter the action of 20(OH)D3 on NF-kappaB activity, since 20(OH)D3 treatment of cells with or without exogenous stimulation had similar effects on p65 localization and IkappaBalpha levels. Although NF-kappaB can be activated through both classical and alternative signaling pathways, previous studies have indicated that IL-1 and LPS activate NF-kappaB through the classical signaling pathway [46]. In this general pathway, p50:p65 dimers are sequestered in the cytoplasm by IkappaB proteins. LPS and IL-1 stimulate IkappaB kinase activity, resulting in the subsequent IkappaB phosphorylation and ubiquitinylation. Then IkappaB is targeted for proteosomal degradation, which allows p50:p65 dimers to translocate to the nucleus, bind to DNA and activate the transcription of NF-kappaB-dependent genes. Consistent with this general pathway we show that both LPS and IL-1 stimulate NF-kappaB transcriptional activity as well as result in IkappaB degradation. Most importantly, we show that 20(OH)D3 acts as an immunosuppressive agent in human keratinocytes by blocking the activation of this signaling pathway by both IL-1 and LPS. 20(OH)D3 not only inhibits the translocation of the p65 NF-kappaB protein from cytoplasm to nucleus in keratinocytes, but also increases the cellular levels of the inhibitory NF-kappaB protein, IkappaB, thus sequestering the NF-kappaB in the cytoplasm as transcriptionally inactive NF-kappaB/IkappaB complexes. Since recent studies demonstrate that activation of the alternative NF-kappaB pathway can also lead to the translocation of p65-containing dimers into the nucleus [42], our data cannot exclude the possibility that 20(OH)D3 also blocks this signaling pathway as well. Detailed analysis of the alternative signaling pathway will be the subject of future studies.
###end p 45
###begin p 46
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 283 289 279 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g008">Fig. 8</xref>
###xml 368 369 364 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 690 691 678 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 905 909 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Masuda1">[49]</xref>
In previous studies we showed that the action of 20(OH)D3 on proliferation and differentiation in keratinocytes requires VDR expression [15]. In the present study we find that silencing VDR expression in keratinocytes blocks the inhibitory actions of 20(OH)D3 on NF-kappaB activity (Fig. 8). Therefore, our data indicates that both 20(OH)D3 (novel ligand) and 1,25(OH)2D3 (classical ligand) suppress NF-kappaB activity through a VDR-mediated signaling pathway. Although the mechanism of this pathway in inhibiting NF-kappaB activity requires more in-depth analysis, our studies demonstrate that 20(OH)D3 can induce anti-inflammatory actions similar to those mediated by calcitriol (1,25(OH)2D3) via the VDR-mediated inhibition of NF-kappaB activity. Interestingly vitamin D analogues are now widely used drugs for the treatment of psoriasis, an inflammatory and hyperproliferative dermatoses (reviewed in [49]). Therefore, we believe that 20(OH)D3 holds promise as a novel therapeutic agent in the prevention and therapy of inflammatory, auto-immune and hyperproliferative skin diseases.
###end p 46
###begin p 47
###xml 128 129 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 132 135 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Lehmann1">[1]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Holick4">[25]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Reichrath1">[67]</xref>
###xml 551 554 539 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski2">[7]</xref>
###xml 556 560 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Tuckey2">[10]</xref>
###xml 676 684 660 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005988-g009">figure 9</xref>
Recently, new and important immunomodulatory effects of vitamin D analogs have been characterized, especially those for 1,25(OH)2D3 [1], [25], [67]. Inhibitors targeting the NF-kappaB signaling pathway effectively suppress NF-kappaB activity, protect and relieve inflammatory symptoms, and induce apoptosis of tumor cells. NF-kappaB represents an attractive drug target for therapy of inflammatory and autoimmune disorders, as well as for cancer. Thus, 20(OH)D3 is a new powerful analog of vitamin D3 that is produced by enzymatic activity of CYP11A1 [7], [10], and have pleiotropic activities through its ability to modulate the NF-kappaB signaling pathway as illustrated in figure 9. Increased expression of IkappaBalpha and inhibition of NF-kappaB activity in keratinocytes induced by 20(OH)D3 may be one mechanism by which this (potentially endogenous) vitamin D analog could exert beneficial effects in inflammatory and auto-immune disorders.
###end p 47
###begin title 48
A schematic representation of the effects of 20(OH)D3 on NFkappaB signal transduction in keratinocytes.
###end title 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
Cell culture
###end title 50
###begin p 51
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Bikle5">[30]</xref>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Lehmann3">[68]</xref>
###xml 358 361 358 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Slominski1">[6]</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Gurlek1">[69]</xref>
###xml 783 787 783 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek1">[15]</xref>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 265 271 <span type="species:ncbi:9913">bovine</span>
###xml 474 480 <span type="species:ncbi:9913">bovine</span>
###xml 629 634 <span type="species:ncbi:9606">human</span>
Immortalized human keratinocytes (HaCaT), which are frequently used for studies on biological effect of 1,25(OH)2D3 [30], [68], were cultured in Dulbecco's Modified Eagle Medium supplemented with glucose, L-glutamine, pyridoxine hydrochloride (Cell Grow), 5% fetal bovine serum (Sigma) and 1% penicillin/streptomycin/amphotericin antibiotic solution (Sigma) [6]. In order to eliminate potential interference by sterols present in the serum [69], 5% charcoal/dextran-treated bovine serum (HyClone) was used to test the effects of active forms of vitamin D. In addition, cells were serum-deprived for 24 h before treatment. Normal human epidermal keratinocytes were isolated from neonatal foreskin (HEKn) and grown in KGM medium supplemented with KGF (Lonza) on collagen-coated plates [15]. For experiments cells in their third passage were used.
###end p 51
###begin title 52
Immunofluorescent staining
###end title 52
###begin p 53
###xml 402 406 <span type="species:ncbi:9925">goat</span>
###xml 412 418 <span type="species:ncbi:9986">rabbit</span>
###xml 434 438 <span type="species:ncbi:9925">goat</span>
###xml 444 450 <span type="species:ncbi:9986">rabbit</span>
###xml 638 642 <span type="species:ncbi:9925">goat</span>
###xml 648 654 <span type="species:ncbi:9986">rabbit</span>
HEKn cells were seeded onto cover glasses in 6-well plate and treated with 100 nM of 20(OH)D3 for 24 h. Control cells were treated with solvent (<0.1% ethanol). After treatment cells were washed in PBS and fixed in 4% paraformaldehyde. Cells were than incubated in permeabilizing solution (0.2% Triton-X 100 in PBS) for 5 min, washed with PBS and blocked in 2% BSA for 30 min. Primary antibody, either goat anti-rabbit-p65 (1:100) or goat anti-rabbit-IkappaB (1:100) in 1% BSA, was added to the cells and incubated overnight at 4degreesC. After extensive washing in PBS, cells were incubated in the secondary antibody solution comprising goat-anti-rabbit-Alexa Fluor 488 (Invitrogen, 1:500 in PBS) and incubated for 1 h at room temperature in the dark. Cells on cover glass were washed and mounted with mounting medium containing propidium iodine (Vectashield). Stained cells were analyzed using a fluorescent microscope at 40x magnification.
###end p 53
###begin title 54
Transfection and Reporter assay
###end title 54
###begin p 55
###xml 76 80 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pisarchik1">[70]</xref>
###xml 109 113 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek2">[63]</xref>
###xml 115 119 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek3">[66]</xref>
The constructs pLuc, pHRLTK and NFkappaB-Luc have been described previously [70]. According to our protocols [63], [66], HaCaT and normal epidermal keratinocytes were transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA) in DMEM or KGM medium, with firefly luciferase reporter gene plasmid and with phRL-TK (expresses Renilla luciferase and serves as normalization control; Promega, Madison, WI). At 24 hr after transfection, the medium was changed and the cells were treated with the vitamin D3 derivatives or vehicle (<0.1% ethanol) for 0.5, 1, 4, 16 and 24 h. Following this protocol, cells were also treated with 10 ng/ml interleukin 1alpha (IL-1alpha) (Sigma) or 1 microg/ml LPS (Sigma) for 30 minutes. The Firefly luciferase and Renilla luciferase signals were recorded with a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA); background luminescence was subtracted and the resulting promoter specific firefly signal was divided by the Renilla signal (proportional to the number of transfected cells). The values obtained were calculated relative to control (untreated) cells, and expressed as relative fold change.
###end p 55
###begin title 56
siRNA transfection
###end title 56
###begin p 57
###xml 103 108 <span type="species:ncbi:9606">human</span>
Keratinocytes were transfected with 2 nM VDR or scrambled siRNA (Dharmacon), on-Target plus smart pool human VDR or on-Target plus siControl non-targeting pool, using lipofectamine plus (Invitrogen) in DMEM medium. Twenty four hours after transfection, cells were treated for an additional 4 h with 100 nM 20(OH)D3 or vehicle (ethanol), mRNA was isolated and used for gene expression analysis or cells were stained for IkappaBalpha or NFkappaB p65 and examined for protein localization by fluorescent microscopy.
###end p 57
###begin title 58
Preparation of cell lysates
###end title 58
###begin p 59
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Hanissian1">[71]</xref>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Hanissian2">[72]</xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Zbytek4">[73]</xref>
###xml 592 593 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 993 997 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pavicevic1">[74]</xref>
###xml 1081 1085 1067 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Riis1">[55]</xref>
###xml 304 309 <span type="species:ncbi:9606">human</span>
Cells were treated with 20(OH)D3 or 1,25(OH)2D3, and whole cell lysates were prepared as described previously [71], [72]. Cells were resuspended in RIPA buffer containing protease inhibitor cocktail (Sigma) and PMSF. Nuclear extracts were prepared as described previously [73]. In brief, HaCaT or normal human keratinocytes were treated with 100 nM 20(OH)D3 for 0, 0.5, 1, 4, 16 or 24 h, and then stimulated with or without interleukin 1alpha (10 ng/ml) for an additional 30 min. The cells were harvested, pelleted and resuspended in STM buffer (20 mM Tris-HCl, 250 mM sucrose and 1.1 mM MgCl2). The nuclear pellet was resuspended in 30 microl nuclear extraction buffer containing 0.4 M KCl, 5 mM 2-mercaptoethanol and protease inhibitor cocktail (1:100 dilution, Sigma) in STM buffer, and incubated on ice for 30 min with intermittent shaking and then centrifuged at 14,000xg for 20 min at 4degreesC. The protein content in the supernatant was quantified using the Bradford protein assay kit [74]. Cytosolic extracts were prepared as described previously with minor modifications [55]. Cell pellets were resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.2 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5% NP40, protease inhibitor cocktail (Sigma) and 20 mM PMSF), and after a 20 min of incubation on ice the suspension was centrifuged at 4degreesC for 10 minutes at 5,000xg. The centrifuged supernatant was considered the cytosolic extract.
###end p 59
###begin p 60
###xml 720 724 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005988-Pavicevic1">[74]</xref>
###xml 136 142 <span type="species:ncbi:9986">rabbit</span>
###xml 348 354 <span type="species:ncbi:9986">rabbit</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
###xml 445 456 <span type="species:ncbi:3704">horseradish</span>
The levels of IkappaBalpha, the p65 NF-kappaB protein, and beta-actin were assessed by immunoblotting. Primary antibodies used were the rabbit polyclonal antibodies directed against IkappaB-alpha (Santa Cruz, 1:500 dilution); p65 (Santa Cruz, 1:500 dilution) and beta-actin-peroxidase (Sigma, 1:5000 dilution). The secondary antibody used was anti rabbit IgG (Santa Cruz, 1:7,000 dilution) and anti-mouse IgG (Santa Cruz, 1:5,000) conjugated to horseradish peroxidase. Signals were detected using ECL kit Supersignal West Pico Chemiluminescent Substrate (Pierce). The intensity of bands was measured using ImageJ Software. Results for whole cell and cytosolic protein levels were expressed relative to beta-actin levels [74]. Levels of VDR and beta-actin 24 h after VDR siRNA transfection were assessed in western blots with (VDR(D-6)) antibody (Santa Cruz, 1:400).
###end p 60
###begin title 61
Electrophoretic mobility shift assay (EMSA)
###end title 61
###begin p 62
DNA binding activity was determined by EMSA using a consensus NF-kappaB IRDye-labeled oligonucleotide probe (LI-COR). The DNA binding reaction consisted of 2.5 to 5 microg of the nuclear extract, the NF-kappaB probe and gel shift binding buffer containing of 2.5 mM DTT, 0.25% Tween-20 and 0.25 mg/ml poly(dI) :poly(dC). The reaction was carried out at room temperature in the dark for 30 min. For supershift assays 1 microg of p65 or p50 antibody (gift of the NCI Preclinical Repository) was added to the nuclear extract prior to DNA binding and incubated for 30 min at 4degreesC. Orange loading dye was added to samples which were loaded on pre-run 5% TBE gels and run at 70 V for 2 h. The gel was scanned using an Odyssey Infrared Imaging System (LI-COR, Inc,. Lincoln, NE).
###end p 62
###begin title 63
Real-time RT PCR
###end title 63
###begin p 64
###xml 77 78 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 608 628 576 596 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTCAAGGAGCTGCAGGAGAT</named-content>
###xml 640 658 608 626 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GATGGCCAAGTGCAGGAA</named-content>
###xml 697 717 661 681 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ACCCTGACCTTGCCTATTTG</named-content>
###xml 729 749 693 713 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGCTCTTTTTCCCGATCTCC</named-content>
###xml 787 806 751 770 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGGGATGGCTTCTATGAGG</named-content>
###xml 818 836 782 800 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CTCCAGGTCCCGCTTCTT</named-content>
###xml 869 887 833 851 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CTTACCTGCCCCCTGCTC</named-content>
###xml 898 916 862 880 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGGGTCAGGCAGGGAAGT</named-content>
###xml 1057 1058 1021 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
The RNA from HaCaT and normal keratinocytes treated with 20(OH)D3 or 1,25(OH)2D3 was isolated using Absolutely RNA Miniprep Kit (Stratagen). Reverse transcription (100 ng/reaction) was performed with Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time PCR was performed using cDNA diluted 10-fold in sterile water and a TaqMan PCR Master Mix (n = 3). Reactions were performed at 50 degreesC for 2 min, 95 degreesC for 10 min and than 50 cycles of 95 degreesC for 15 s, 60 degreesC for 1 min). The primers and probes were designed with universal probe library (Roche): IkappaBalpha primers (left: GTCAAGGAGCTGCAGGAGAT and right: GATGGCCAAGTGCAGGAA), probe #38; NFkappaB1 primers (left: ACCCTGACCTTGCCTATTTG and right: AGCTCTTTTTCCCGATCTCC), probe #39; and RelA primers (left: CGGGATGGCTTCTATGAGG and right: CTCCAGGTCCCGCTTCTT), probe #47; VDR primers (left: CTTACCTGCCCCCTGCTC and right AGGGTCAGGCAGGGAAGT), probe #58. The data was collected on a Roche Light Cycler 480. The amounts of product were compared to Cyclophilin B using a comparative CT method.
###end p 64
###begin title 65
Statistical analysis
###end title 65
###begin p 66
Data are presented as means+/-STDEV and were analyzed with Student's t-test (for 2 groups) and one-way Anova with appropriate post-hoc test (for more than 2 groups) using Excel (Microsoft) and Prism 4.00 (GraphPad Software, San Diego), respectively. Statistically significant differences are denoted with asterisks: *P<0.05, **P<0.001.
###end p 66
###begin p 67
We thank Dr William Taylor at the Molecular Resource Center, University of Tennessee Health Science Center for helpful comments regarding qPCR experiments. We also thank Dr Irina Nosrat for help in fluorescent microscopy.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
Vitamin D and skin: new aspects for dermatology.
###end article-title 69
###begin article-title 70
Vitamin D: A millenium perspective.
###end article-title 70
###begin article-title 71
Vitamin D: production, metabolism and mechanism of action.
###end article-title 71
###begin article-title 72
Who, what, where and when-influences on cutaneous vitamin D synthesis.
###end article-title 72
###begin article-title 73
The photobiogenesis and metabolism of vitamin D.
###end article-title 73
###begin article-title 74
Enzymatic metabolism of ergosterol by cytochrome p450scc to biologically active 17alpha,24-dihydroxyergosterol.
###end article-title 74
###begin article-title 75
The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism.
###end article-title 75
###begin article-title 76
A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin.
###end article-title 76
###begin article-title 77
Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3.
###end article-title 77
###begin article-title 78
Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc.
###end article-title 78
###begin article-title 79
Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin.
###end article-title 79
###begin article-title 80
An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2.
###end article-title 80
###begin article-title 81
###xml 30 35 <span type="species:ncbi:9606">human</span>
Progesterone synthesis by the human placenta.
###end article-title 81
###begin article-title 82
###xml 26 31 <span type="species:ncbi:9606">human</span>
The vitamin D3 pathway in human skin and its role for regulation of biological processes.
###end article-title 82
###begin article-title 83
20-Hydroxyvitamin D3, a Product of Vitamin D3 Hydroxylation by Cytochrome P450scc, Stimulates Keratinocyte Differentiation.
###end article-title 83
###begin article-title 84
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.
###end article-title 84
###begin article-title 85
Vitamin D and skin cancer.
###end article-title 85
###begin article-title 86
Vitamin D and cancer.
###end article-title 86
###begin article-title 87
Vitamin D and vitamin D analogs in cancer treatment.
###end article-title 87
###begin article-title 88
Vitamin D and cancer.
###end article-title 88
###begin article-title 89
Vitamin D deficiency.
###end article-title 89
###begin article-title 90
Vitamin D.
###end article-title 90
###begin article-title 91
Noncalcemic actions of vitamin D receptor ligands.
###end article-title 91
###begin article-title 92
Novel Gemini vitamin D(3) analogs have potent antitumor activity.
###end article-title 92
###begin article-title 93
Evolution and function of vitamin D.
###end article-title 93
###begin article-title 94
Vitamin D regulated keratinocyte differentiation.
###end article-title 94
###begin article-title 95
Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action.
###end article-title 95
###begin article-title 96
Vitamin D deficiency: what a pain it is.
###end article-title 96
###begin article-title 97
What is new in vitamin D: 2006-2007.
###end article-title 97
###begin article-title 98
Calcium- and vitamin D-regulated keratinocyte differentiation.
###end article-title 98
###begin article-title 99
Calcium and vitamin D. Diagnostics and therapeutics.
###end article-title 99
###begin article-title 100
Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation.
###end article-title 100
###begin article-title 101
NF-kappaB regulation in the immune system.
###end article-title 101
###begin article-title 102
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
###end article-title 102
###begin article-title 103
IKKalpha is required to maintain skin homeostasis and prevent skin cancer.
###end article-title 103
###begin article-title 104
Inhibition of tumor growth by NF-kappaB inhibitors.
###end article-title 104
###begin article-title 105
Keratinocytes and cytokines.
###end article-title 105
###begin article-title 106
Keratins and the keratinocyte activation cycle.
###end article-title 106
###begin article-title 107
Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling.
###end article-title 107
###begin article-title 108
Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes.
###end article-title 108
###begin article-title 109
Shared principles in NF-kappaB signaling.
###end article-title 109
###begin article-title 110
Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway.
###end article-title 110
###begin article-title 111
NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity.
###end article-title 111
###begin article-title 112
Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival.
###end article-title 112
###begin article-title 113
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
###end article-title 113
###begin article-title 114
Two pathways to NF-kappaB.
###end article-title 114
###begin article-title 115
Psoriasis.
###end article-title 115
###begin article-title 116
An orphan meets family members in skin.
###end article-title 116
###begin article-title 117
Promise of vitamin D analogues in the treatment of hyperproliferative conditions.
###end article-title 117
###begin article-title 118
Sequential regulation of keratinocyte differentiation by 1,25(OH)2D3, VDR, and its coregulators.
###end article-title 118
###begin article-title 119
Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation.
###end article-title 119
###begin article-title 120
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3.
###end article-title 120
###begin article-title 121
Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3.
###end article-title 121
###begin article-title 122
Death penalty for keratinocytes: apoptosis versus cornification.
###end article-title 122
###begin article-title 123
###xml 81 86 <span type="species:ncbi:9606">human</span>
1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression.
###end article-title 123
###begin article-title 124
The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages.
###end article-title 124
###begin article-title 125
Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels.
###end article-title 125
###begin article-title 126
Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor.
###end article-title 126
###begin article-title 127
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling.
###end article-title 127
###begin article-title 128
###xml 100 105 <span type="species:ncbi:9606">human</span>
Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes.
###end article-title 128
###begin article-title 129
Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin.
###end article-title 129
###begin article-title 130
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives.
###end article-title 130
###begin article-title 131
###xml 74 79 <span type="species:ncbi:9606">human</span>
Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes.
###end article-title 131
###begin article-title 132
The IKK NF-kappa B system: a treasure trove for drug development.
###end article-title 132
###begin article-title 133
An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells.
###end article-title 133
###begin article-title 134
###xml 56 61 <span type="species:ncbi:9606">human</span>
Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes.
###end article-title 134
###begin article-title 135
Ultraviolet light (UV)-induced immunosuppression: is vitamin D the missing link?
###end article-title 135
###begin article-title 136
###xml 63 68 <span type="species:ncbi:9606">human</span>
HaCaT cell line as a model system for vitamin D3 metabolism in human skin.
###end article-title 136
###begin article-title 137
Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation.
###end article-title 137
###begin article-title 138
Molecular and functional characterization of novel CRFR1 isoforms from the skin.
###end article-title 138
###begin article-title 139
cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP.
###end article-title 139
###begin article-title 140
Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma.
###end article-title 140
###begin article-title 141
###xml 37 42 <span type="species:ncbi:9606">human</span>
CRH inhibits NF-kappa B signaling in human melanocytes.
###end article-title 141
###begin article-title 142
cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells.
###end article-title 142
###begin p 143
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 143
###begin p 144
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NIH grant R01AR052190. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 144

